Cargando…
Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722988/ https://www.ncbi.nlm.nih.gov/pubmed/31370361 http://dx.doi.org/10.3390/jcm8081145 |
_version_ | 1783448668922183680 |
---|---|
author | Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Suyeon Jung, Kwang-Young Kim, Hyoungnae Kwon, Soon Hyo Jeon, Jin Seok Han, Dong Cheol Noh, Hyunjin |
author_facet | Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Suyeon Jung, Kwang-Young Kim, Hyoungnae Kwon, Soon Hyo Jeon, Jin Seok Han, Dong Cheol Noh, Hyunjin |
author_sort | Lee, Hee Jeong |
collection | PubMed |
description | Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75–0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications. |
format | Online Article Text |
id | pubmed-6722988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67229882019-09-10 Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Suyeon Jung, Kwang-Young Kim, Hyoungnae Kwon, Soon Hyo Jeon, Jin Seok Han, Dong Cheol Noh, Hyunjin J Clin Med Article Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75–0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of β2AR agonists may exert a protective effect against diabetic vascular complications. MDPI 2019-07-31 /pmc/articles/PMC6722988/ /pubmed/31370361 http://dx.doi.org/10.3390/jcm8081145 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Hee Jeong Lee, Haekyung Oh, Song Hee Park, Suyeon Jung, Kwang-Young Kim, Hyoungnae Kwon, Soon Hyo Jeon, Jin Seok Han, Dong Cheol Noh, Hyunjin Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title_full | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title_fullStr | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title_full_unstemmed | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title_short | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study |
title_sort | association between beta2-adrenergic receptor agonists and the risk of vascular complications in diabetic patients: a population-based cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722988/ https://www.ncbi.nlm.nih.gov/pubmed/31370361 http://dx.doi.org/10.3390/jcm8081145 |
work_keys_str_mv | AT leeheejeong associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT leehaekyung associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT ohsonghee associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT parksuyeon associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT jungkwangyoung associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT kimhyoungnae associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT kwonsoonhyo associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT jeonjinseok associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT handongcheol associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy AT nohhyunjin associationbetweenbeta2adrenergicreceptoragonistsandtheriskofvascularcomplicationsindiabeticpatientsapopulationbasedcohortstudy |